DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
1401 Rockville Pike
Rockville MD 20852-1448

December 30, 1996

Our Reference Number: 96-0576

Dennis J. Foley, Ph.D.
Lederle Laboratories Division
American Cyanamid Company
Middletown Road
Pearl River, NY 10965

Dear Dr. Foley:

The Supplement to your Product License Application for Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) to include the use of this product for the primary series in infants has been approved.

This product is currently licensed in the U.S. for use as a fourth and fifth dose in children. With the approval of this Supplement ACEL-IMUNE™ (DTaP) may now be used for a three dose primary series in children at least six weeks of age and for the fourth and fifth dose in children who have received three doses of DTaP or Diphtheria and Tetanus Toxoids and Pertussis Vaccine Adsorbed (whole cell pertussis).

This approval also includes a modified formulation in single and multiple dose vials for which the target aluminum concentration of 0.23 mg/0.5 mL dose (1409 formulation) replaces the previous concentration of 0.15 mg/0.5 mL dose (1407 formulation). The dating period for the newly formulated product in single and multiple dose vial presentations shall be 36 months from the date of manufacture when stored at 2-8°C, to include 12 months in manufacturer's storage and up to 24 months in distribution. The dating period of the final combination is based on the component with the shortest dating period and/or the first valid potency test, whichever time period is the shortest [21 CFR 610.50(a) and 21 CFR 610.53(b)].

We acknowledge the following commitments made in your correspondence dated December 9, 13 and 17, 1996:

1. You have agreed to conduct a post-marketing surveillance study under IND 2417, with enrollment to begin the first quarter of 1997, to assess the occurrence of rare events when ACEL-IMUNE™ is administered in a primary series to approximately 30,000 infants at 2, 4 and 6 months of age.

2. You have agreed to conduct a post-marketing study under IND 2417, with enrollment to begin the first quarter of 1997, to assess the safety of the fifth dose after 4 previous doses of ACEL-IMUNE™ in approximately 240 children.

3. Upon approval of this Supplement, you have agreed to stop distribution of the 1407 formulation. In addition, a letter to physicians will be distributed stating that the 1407 formulation product is not approved for use in infants for the primary series.

4. You have agreed to submit a Supplement for a new potency assay for the pertussis component for the 1409 formulation product. The submission of this Supplement is to occur by the end of the first quarter of 1997.

This information will be included in your Product License Application File.

Please submit three copies of final printed labeling at the time of use and include part II of the Transmittal of Labels form FDA 2567 with completed implementation information. In addition, you may wish to submit your proposed introductory advertising and promotional campaign. If so, please submit three (3) copies of the proposed material in draft form with Part I of FDA form 2567 to the Center for Biologics Evaluation and Research (CBER), Advertising and Promotional Labeling Staff (APLS), HFM-202, 1401 Rockville Pike, Rockville, MD 20852-1448. Promotional claims should be consistent with and not contrary to approved labeling. No comparative claim of superiority over other similar products should be made unless data to support such claims are submitted to and approved by CBER. Final copies of advertising and promotional materials should be submitted at the time of use with Part II of FDA form 2567 to APLS. Please include copies of the approved labeling with your proposed or final copy of advertising and promotional material submitted to CBER.

It is requested that adverse reports for Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, be submitted in accordance with the adverse experience reporting requirements for licensed biological products pursuant to Title 21 of the Code of Federal Regulations Part 600.80 and that distribution of reports be submitted to the Vaccines Adverse Event Reporting System (VAERS) using the pre-addressed form VAERS-1.

Sincerely yours,

for M. Carolyn Hardegree, M.D.
Director
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research